A Study To Assess The Safety, Tolerability And Anti-tumour Activity Of Ascending Doses Of Selumetinib In Combination With MEDI4736 And Selumetinib In Combination With MEDI4736 And Tremelimumab In Patients With Advanced Solid Tumours

Study Overview

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

This is a Phase I, open-label, multi-centre, drug combination study of double and triple combination oral selumetinib (AZD6244 Hyd-sulfate) plus intravenous (IV) MEDI4736 and oral selumetinib plus IV MEDI4736 and IV tremelimumab in patients with advanced solid tumours refractory to standard therapy or for which no standard therapy exists. The safety, tolerability, and preliminary anti-tumour activity of ascending doses of Selumetinib (AZD6244 Hyd-sulfate) in Combination with MEDI4736 and Selumetinib in Combination with MEDI4736 and Tremelimumab will be investigated. Once safety and tolerability have been established for the relevant dose, expansion cohorts will commence in order to further evaluate safety, tolerability, and provide a preliminary evaluation of the mechanism of action and anti-tumour activity of the drug combination. Mandatory paired biopsy expansion cohorts will be tumour-type specific. Expansion cohorts will open independently for double and triple combination treatments.

Lung Cancer
Melanoma
Head and Neck Carcinoma
Gastroesophageal Cancer
Breast Cancer
Pancreatic Adenocarcinoma
Colorectal Cancer
Biliary Tract Cancer

DRUG: Selumetinib
DRUG: MEDI4736
DRUG: Tremelimumab

D1345C00003

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates	Results Reporting Dates	Study Record Updates
First Submitted 2015-09-21	Results First Submitted N/A	Last Update Submitted that met QC Criteria 2019-11-15
First Submitted that Met QC Criteria 2015-10-23	Results First Submitted that Met QC Criteria N/A	Last Update Posted (ACTUAL) 2019-11-18
First Posted (ACTUAL) 2015-10-27	Results First Posted N/A	Last Verified 2019-11

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment

Allocation:
Non Randomized

Interventional Model:
Parallel

Masking:
None

Arms and Interventions

Participant Group/Arm	Intervention/Treatment
EXPERIMENTAL: Dose escalation: Selumetinib+MEDI4736 An oral formulation of selumetinib will be administered in combination with an IV dose of MEDI4736. 4 cohorts of double combination (Selumetinib+MEDI4736). The decision to escalate to the next dose level/cohort will be made by the Safety Review Committee	DRUG: Selumetinib Selumetinib oral DRUG: MEDI4736 MEDI4736 IV DRUG: Tremelimumab Tremelimumab, IV
EXPERIMENTAL: Mandatory paired biopsy expansion cohort: Selumetinib+MEDI4736 One or more independent mandatory paired biopsy expansion cohorts for double combination treatment will start after safety and tolerability have been established for the relevant dose. It will be tumour-type specific for double combination, the tumor type	DRUG: Selumetinib Selumetinib oral DRUG: MEDI4736 MEDI4736 IV
EXPERIMENTAL: Dose escalation: Selumetinib+MEDI4736+tremelimumab An oral formulation of selumetinib will be administered in combination with an IV dose of MEDI4736 and an IV dose of tremelimumab. For triple combination treatment, the starting dose of selumetinib (DL1) will be determined by the SRC based on emerging da	DRUG: Selumetinib Selumetinib oral DRUG: MEDI4736 MEDI4736 IV DRUG: Tremelimumab Tremelimumab, IV
EXPERIMENTAL: Mandatory paired biopsy expansion cohort: triple combination One or more independent mandatory paired biopsy expansion cohorts for triple combination treatment will start after safety and tolerability have been established for the relevant dose. It will be tumour-type specific for triple combination, the tumor type	DRUG: Selumetinib Selumetinib oral DRUG: MEDI4736 MEDI4736 IV DRUG: Tremelimumab Tremelimumab, IV

Primary Outcome Measures	Measure Description	Time Frame
Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of Adverse Events		From screening until approximately 30 days after last dose of study drug at disease progression
Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of safety laboratory tests		From screening until approximately 30 days after last dose of study drug at disease progression
Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of blood pressure (BP)		From screening until approximately 30 days after last dose of study drug at disease progression
Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of Electrocardiogram (ECG)		From screening until approximately 30 days after last dose of study drug at disease progression
Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of physical examinations		From screening until approximately 30 days after last dose of study drug at disease progression
Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of Echocardiogram (ECHO)		From screening until approximately 30 days after last dose of study drug at disease progression
Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of pulse		From screening until approximately 30 days after last dose of study drug at disease progression
Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of body temperature		From screening until approximately 30 days after last dose of study drug at disease progression
Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of respiratory rate		From screening until approximately 30 days after last dose of study drug at disease progression
Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of Multigated Acquisition (MUGA)		From screening until approximately 30 days after last dose of study drug at disease progression
Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of Ophthalmic examination (best corrected visual acuity)		From screening until approximately 30 days after last dose of study drug at disease progression
Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of Ophthalmic examination (Intraocular pressure)		From screening until approximately 30 days after last dose of study drug at disease progression
Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of Ophthalmic examination (slit lamp fundoscopy)		From screening until approximately 30 days after last dose of study drug at disease progression

Secondary Outcome Measures	Measure Description	Time Frame
Long-term tolerated dose and exposure predicted to result in biological activity (including but not limited to Response Evaluation Criteria in Solid Tumours (RECIST)		From screening until 30 days after last dose of study drug at disease progression, approximately 6 months however there is no maximum duration of treatment
Objective response rate (ORR)		From screening until 30 days after last dose of study drug at disease progression, approximately 6 months however there is no maximum duration of treatment
Change in tumour size		From screening until 30 days after last dose of study drug at disease progression, approximately 6 months however there is no maximum duration of treatment
Best Objective Response (BoR)		From screening until 30 days after last dose of study drug at disease progression, approximately 6 months however there is no maximum duration of treatment
Duration of Response (DoR)		From screening until 30 days after last dose of study drug at disease progression, approximately 6 months however there is no maximum duration of treatment
Progression-free survival (PFS)		From screening until 30 days after last dose of study drug at disease progression, approximately 6 months however there is no maximum duration of treatment
Overall survival (OS)		From screening until 30 days after last dose of study drug at disease progression, approximately 6 months however there is no maximum duration of treatment
MEDI4736 and/or tremelimumab anti-drug antibody (ADA) level in Plasma		From screening until 30 days after last dose of study drug at disease progression, approximately 6 months however there is no maximum duration of treatment

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

Postmenopausal defined as aged more than 50 years and amenorrhoeic for at least 12 months following cessation of all exogenous hormonal treatments
Women <50 years old would be considered postmenopausal if they have been amenorrheic for the past 12 months or more following cessation of exogenous hormonal treatments. The levels of luteinising hormone (LH) and follicle stimulating hormone (FSH) must also be in the postmenopausal range (as per the institution)
Documentation of irreversible surgical sterilisation by hysterectomy and / or bilateral oophorectomy and/or bilateral salpingectomy but not tubal ligation 7. Male patients should be willing to use barrier contraception ie, condoms plus spermicide 8. Mandatory provision of tumour tissue sample available at study entry for exploratory biomarker research. Cytology samples for this exploratory biomarker research will not be acceptable 9. Patients must have mCRC and, if MSI status is known, non-high MSI status. MSI status will be evaluated based on previous results of local MSI testing, if available. Patients with known MSI-high status will be excluded; patients with MSS, MSI-low, or unknown MSI status may be enrolled

Cytotoxic chemotherapy or other anticancer drugs within 28 days of the 1st dose of study treatment or any investigational agents within 5 half-lives of the product
MEDI4736 or selumetinib in the present study (ie, dosing with MEDI4736 or selumetinib previously initiated in this study)
Major surgical procedure, (excluding placement of vascular access) or significant traumatic injury within 4 weeks of the 1st dose of study treatment, or have an anticipated need for major surgery during the study
Palliative radiotherapy with a wide field of radiation within 4 weeks or radiotherapy with a limited field of radiation for palliation within 2 weeks of the 1st dose of study treatment
Prior exposure to immune-mediated therapy, including, but not limited to, other anti-CTLA- 4 (Cytotoxic T-lymphocyte antigen-4), anti-PD-1 (Programmed cell death 1), anti-PD-L1 (Programmed cell death ligand 1), or anti-PD-L2 (Programmed cell death ligand 2) antibodies, including therapeutic anticancer vaccines
Receipt of live attenuated vaccine within 30 days prior to the first dose of IP
Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study 3. Any unresolved toxicity NCI CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events) Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria

Patients with Grade ≥2 neuropathy will be evaluated on a case-by-case basis and may be included after consultation with the medical monitor
Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with selumetinib, MEDI4736 or tremelimumab may be included after consultation with the medical monitor 4. History of leptomeningeal carcinomatosis and brain metastases or spinal cord compression. Patients with suspected brain metastases at screening should have a CT / MRI of the brain prior to study entry 5. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [eg, colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], celiac disease, irritable bowel disease, or other serious GI (Gastrointestinal) chronic conditions associated with diarrhoea, systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [eg, granulomatosis with polyangiitis, Graves' disease; rheumatoid arthritis, hypophysitis, uveitis]) within the past 3 years prior to the start of treatment. The following are exceptions to this criterion:

Patients with vitiligo or alopecia
Patients with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement or psoriasis not requiring systemic treatment 6. History of active primary immunodeficiency 7. Current or prior use of immunosuppressive medication within 14 days before the 1st dose of MEDI4736. The following are exceptions to this criterion:

Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra-articular injection)
Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent
Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication) 8. As judged by the investigator, any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, renal transplant, active bleeding diatheses, which in the investigator's opinion makes it undesirable for the patient to participate in the study or which would jeopardise compliance with the protocol or active infection including hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody or human immunodeficiency virus (HIV) or known history of clinical diagnosis of tuberculosis 9. Screening for chronic conditions is not required 10. Any of the following cardiac criteria:

Any factors that increase the risk of QT(ECG interval measured from the onset of the QRS complex to the end of the T wave) interval corrected for heart rate (QTc) prolongation or risk of arrhythmic events (eg, heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age) or mean QTc >470 msec
Uncontrolled hypertension (eg, BP ≥150/95 mmHg despite medical therapy)
Acute coronary syndrome within 6 months prior to starting treatment
Angina Canadian Cardiovascular Society Grade II-IV (despite medical therapy)
Symptomatic heart failure (New York Heart Association II-IV)
Prior or current cardiomyopathy
Baseline LVEF (Left ventricular ejection fraction) <55% measured by echocardiography or MUGA. Appropriate correction to be used if a MUGA is performed.
Atrial fibrillation with a ventricular rate >100 beats per minute at rest
Severe valvular heart disease 11. Any of the following ophthalmic criteria:

Current or past history of central serous retinopathy, detachment of retinal pigmented epithelium, or retinal vein occlusion
Intraocular pressure (IOP) >21 mmHg
Uncontrolled glaucoma (irrespective of IOP) 12. Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:

Absolute neutrophil count <1.5 x 109/L
Platelet count <100 x 109/L
Haemoglobin <90 g/L
Alanine aminotransferase >2.5 x ULN (upper limit of normal) if no demonstrable liver metastases or >5 times ULN in the presence of liver metastases
Aspartate aminotransferase >2.5 x ULN if no demonstrable liver metastases or >5 times ULN in the presence of liver metastases
Serum bilirubin ≤1.5 x ULN. This will not apply to patients with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinaemia [predominantly unconjugated bilirubin] in the absence of evidence of haemolysis or hepatic pathology), who will be allowed in consultation with their physician
Creatinine clearance <50 mL/min (calculated by Cockcroft and Gault equation). Confirmation of creatinine clearance is only required when creatinine is >1.5 times ULN 13. Refractory nausea and vomiting, chronic GI diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of selumetinib 14. History of hypersensitivity to active or inactive excipients of MEDI4736 or selumetinib or drugs with a similar chemical structure or class to MEDI4736 or selumetinib 15. Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements 16. Involvement in the planning and conduct of the study (applies to both AZ staff or staff at the study site) 17. Previous allogeneic bone marrow transplant 18. Body weight <30 kg

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

PRINCIPAL_INVESTIGATOR: Pasi A. Jänne, MD, PhD, Dana-Farber Cancer Institute

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available

Learn

Resources

Patients

Caregivers

Clinical Trial Record